We are delighted to announce that Pauli Wong, Partner at Eagle IP, has been invited to speak at the Entrepreneurship Series 2026, organized by the Hong Kong Life Sciences Society (HKLSS).

Pauli will lead an essential session titled "Protecting Innovation through IP and Legal Strategy," tailored specifically for the next generation of life sciences entrepreneurs, researchers, and biotech professionals. In an industry where intellectual property is often the most valuable asset a company owns, this seminar aims to equip participants with the strategic mindset needed to safeguard their scientific breakthroughs.

At Eagle IP, we are committed to empowering the local life sciences ecosystem. We are proud to partner with HKLSS in their mission to nurture talent and bridge the gap between academic excellence and commercial success in the life sciences sector.

Our Past Events

Recommended Insights

Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

How to Protect a Crystal Form (Polymorph) Patent in China

4 June 2025
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

Stay Ahead: Getting a Chinese Patent in Three Months?

23 April 2024
The China National Intellectual Property Administration (CNIPA) has announced a significant development in the realm of patent prosecution: the initiation of the "PPH Improvement Initiative" in collaboration with key patent offices from the United States, Europe, Japan, and South Korea. This initiative aims to elevate the user experience of the Patent Prosecution Highway (PPH) by […]

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

27 February 2026
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]
Top crossarrow-right